Emerging Options for BRCA-Mutated Breast Cancer Treatment

Video

Related Videos
Erin Frances Cobain, MD
Erin Frances Cobain, MD
Video 6 - "Shared Decision Making and Multidisciplinary Collaboration in the Evolving HR+/HER2- Early-Stage Breast Cancer Landscape"
Manmeet Singh Ahluwalia, MD
D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
Rita Nanda, MD
Video 5 - "AE Management with CDK4/6 Inhibitors: Strategies for Treatment Continuity and Optimal Patient Outcomes"
Rita Nanda, MD
Related Content
Erin Frances Cobain, MD, of the University of Michigan Rogel Cancer Center

Ongoing Research Drives Further Questions in Early-Stage Breast Cancer Management

May 2nd 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Yuankai Shi, MD, PhD, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Glecirasib Generates Durable Responses in Pretreated Advanced KRAS G12C+ NSCLC

April 30th 2024
Article
Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

January 11th 2024
Podcast
Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca

Trastuzumab Deruxtecan Improves PFS in Metastatic HR+/HER2-Low Breast Cancer After Endocrine Therapy

April 29th 2024
Article
Mafalda Oliveira, MD, PhD

CHMP Recommends Capivasertib/Fulvestrant for Pretreated ER+/HER2– Advanced Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

April 29th 2024
Article